Novo-Nordisk A/S
NVO Real Time Price USDRecent trades of NVO by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,300,000 Jul 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,290,000 Apr 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,120,000 Jan 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Skin retention device for a medical jet injection kit Feb. 18, 2014
-
Patent Title: Double-acylated glp-1 derivatives Feb. 11, 2014
-
Patent Title: Injection device Feb. 04, 2014
-
Patent Title: Device and method for contact free absolute position determination Jan. 28, 2014
-
Patent Title: Method of acylating a peptide or protein Jan. 28, 2014
-
Patent Title: Compositions and methods for regulating nk cell activity Jan. 28, 2014
-
Patent Title: Glycopegylated erythropoietin Jan. 21, 2014
-
Patent Title: Glycopegylated factor ix Jan. 21, 2014
-
Patent Title: Injection device with electronic detecting means Jan. 21, 2014
-
Patent Title: Mechanism for injection device Jan. 21, 2014
-
Patent Title: Medical delivery system comprising a coding mechanism Jan. 21, 2014
-
Patent Title: Antibodies against tissue factor pathway inhibitor (tfpi) Dec. 31, 2013
-
Patent Title: Medical delivery system comprising a container and a dosing assembly with radially moving fastening means Dec. 31, 2013
-
Patent Title: Stabilized pharmaceutical peptide compositions Dec. 24, 2013
-
Patent Title: Anti-c5a receptor antibodies Dec. 24, 2013
-
Patent Title: Medical delivery system with asymmetrical coding means Dec. 24, 2013
-
Patent Title: Injection device for apportioning set doses Dec. 17, 2013
-
Patent Title: Impulse chamber for jet delivery device Dec. 17, 2013
-
Patent Title: Contact free reading of cartridge identification codes Dec. 17, 2013
-
Patent Title: Extended glp-1 compounds Dec. 10, 2013
-
Patent Title: Urea glucokinase activators Nov. 19, 2013
-
Patent Title: Needle mounting system and a method for mounting a needle assembly Nov. 12, 2013
-
Patent Title: Medical delivery system with flexible blocking element Nov. 12, 2013
-
Patent Title: Needle magazine Nov. 12, 2013
-
Patent Title: Rapid acting insulin analogues Nov. 05, 2013
-
Patent Title: Amylin analogues and pharmaceutical compositions thereof Nov. 05, 2013
-
Patent Title: Amylin analogues and pharmaceutical compositions thereof Nov. 05, 2013
-
Patent Title: Coupling for injection devices Nov. 05, 2013
-
Patent Title: Non-porous material as sterilization barrier Oct. 15, 2013
-
Patent Title: Ddr1-mediated cell purification of pancreatic endocrine cells through their progenitors Oct. 08, 2013
-
Patent Title: Fluid infusion system, a method of assembling such system and drug reservoir for use in the system Oct. 08, 2013
-
Patent Title: Glucagon analogues Sep. 24, 2013
-
Patent Title: Conjugated factor viii molecules Sep. 17, 2013
-
Patent Title: Acylated glp-1 compounds Sep. 17, 2013
-
Patent Title: Processing of peptides and proteins Sep. 10, 2013
-
Patent Title: Method for preventing formation of trisulfide derivatives of polypeptides Sep. 10, 2013
-
Patent Title: Drug delivery device with cap functions for needle assembly Sep. 10, 2013
-
Patent Title: Method for making maturated insulin polypeptides in a fungal cell Aug. 27, 2013
-
Patent Title: Dry mouldable drug formulation Aug. 27, 2013
-
Patent Title: Stable growth hormone compounds resistant to proteolytic degradation Aug. 20, 2013
-
Patent Title: User interface for delivery system comprising diary function Aug. 13, 2013
-
Patent Title: Amylin derivatives Jul. 16, 2013
-
Patent Title: Insulin derivatives Jul. 02, 2013
-
Patent Title: Il-21 variants Jul. 02, 2013
-
Patent Title: Solid dose micro implant Jun. 04, 2013
-
Patent Title: Il-21 derivatives and variants May. 28, 2013
-
Patent Title: Injection device May. 21, 2013
-
Patent Title: Electronic device assembly with safety electric connector May. 07, 2013
-
Patent Title: Injection device with rotatable dose setting Apr. 16, 2013
-
Patent Title: Counteracting drug-induced obesity using glp-1 agonists Apr. 02, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
We estimate that -- received a compensation of -- in --, making them the highest paid executive at NVO, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|